Quantum Surgical completes first round of financing to accelerate the development of its robotic platform for minimally invasive therapies in liver cancer

Montpellier and Hong Kong, June 4, 2018 – Quantum Surgical SAS, a company specializing in the design of next-generation solutions for the minimally invasive treatment of cancer, announces the completion of its first capital raise with Ally Bridge Group (ABG), a global investment group focused on life sciences. This Series A funding is the first tranche of a total $50 million financing round led by Ally Bridge Group.

Quantum Surgical is developing a next-generation robotic platform dedicated to the minimally invasive treatment of liver cancer. As this disease is the second leading cause of cancer-related death and affects more than 800,000 new patients each year worldwide, Quantum Surgical aims to provide healthcare professionals with new tools to better serve patients by offering a genuine alternative to current treatments.

“Quantum Surgical’s ambition is to establish new standards in cancer treatment by enabling more patients to access innovative, targeted, and less invasive therapies. We are thrilled to be working once again with Ally Bridge Group after our successful collaboration in 2015–2016. This new partnership will allow Quantum Surgical to leverage the group’s strong industrial outlook, international network, and solid financial capacity, as well as its expertise in accessing major medical markets such as the United States, China, and Europe,” said Bertin Nahum, Founder and President of Quantum Surgical.

“ABG is excited to support the Quantum Surgical team led by Bertin Nahum once again in their entrepreneurial journey, following our successful investment in Medtech SA. The team is recognized and has a proven track record in the development and global commercialization of innovative surgical robots. ABG has worked closely with Quantum Surgical since its inception. Our partnership is now at the forefront of creating next-generation robotics to support interventional oncology treatments, particularly for patients with early-stage cancer,” said Frank Yu, Founder and CEO of Ally Bridge Group. “Quantum Surgical is a natural extension of ABG’s recent $300 million investment in GRAIL, an innovative U.S. company focused on the early detection of cancer. ABG has the expertise to forge strategic partnerships between emerging companies and industry leaders at a global level, especially across the U.S., China, and Europe.”